How many stocks does RA CAPITAL MANAGEMENT, L.P. own?

As of Q4 2018, RA CAPITAL MANAGEMENT, L.P. holds 25 positions in their 13F portfolio.

What is RA CAPITAL MANAGEMENT, L.P.'s largest holding?

WVE at 18.4% of portfolio, worth $315.8M.

What is RA CAPITAL MANAGEMENT, L.P.'s total portfolio value?

$1.7B as of Q4 2018, tracked across 25 holdings.

Is RA CAPITAL MANAGEMENT, L.P. a hedge fund?

RA CAPITAL MANAGEMENT, L.P. is an institutional investment manager required to file SEC 13F reports. This includes hedge funds, mutual funds, pension funds, and other institutions managing over $100M.

How often does RA CAPITAL MANAGEMENT, L.P. report?

13F filings are due quarterly, approximately 45 days after each quarter end.

How has RA CAPITAL MANAGEMENT, L.P.'s portfolio changed in Q4 2018?

View RA CAPITAL MANAGEMENT, L.P.'s latest portfolio changes, new positions, and exits for Q4 2018 on HoldingsIntel.

What is RA CAPITAL MANAGEMENT, L.P.'s investment strategy?

RA CAPITAL MANAGEMENT, L.P. is classified as a Balanced Allocator fund based on HoldingsIntel's Fund DNA analysis of 6 behavioral dimensions.

RA CAPITAL MANAGEMENT, L.P.

Institutional investor · Portfolio as of Q4 2018

Top Holdings25 positions

Checking export access…

Activity:

				Price Trend
WVE WAVE LIFE SCIENCES LTD	7.5M	$315.8M	18.4%	—	$42.29	0.00%	1 qtr	First report 0
ASND ADR ASCENDIS PHARMA A/S	4.2M	$265.7M	15.5%	—	$59.89	0.00%	1 qtr	First report 0
THORDelisted Synthorx Inc	9.7M	$169M	9.8%	—	—	—	1 qtr	First report 0
ZGNXDelisted ZOGENIX INC	2.4M	$86.9M	5.1%	—	—	—	1 qtr	First report 0
BCRX BIOCRYST PHARMACEUTICALS INC	10.7M	$86M	5.0%	—	$8.07	0.00%	1 qtr	First report 0
ORTXDelisted ADR ORCHARD THERAPEUTICS PLC	4.8M	$76.2M	4.4%	—	—	—	1 qtr	First report 0
IFRX INFLARX NV	2.1M	$75.8M	4.4%	—	$32.04	0.00%	1 qtr	First report 0
SOLID BIOSCIENCES INC COM NEW(SLDBN)Delisted	2.7M	$72.1M	4.2%	—	—	—	1 qtr	First report 0
MYOV MYOVANT SCIENCES LTD	3.7M	$60.9M	3.5%	—	—	—	1 qtr	First report 0
EIDXDelisted EIDOS THERAPEUTICS INC	2.2M	$59.2M	3.4%	—	—	—	1 qtr	First report 0
CRNXDelisted CRINETICS PHARMACEUTICALS IN	1.9M	$56.2M	3.3%	—	$30.51	0.00%	1 qtr	First report 0
RYTM RHYTHM PHARMACEUTICALS INC	2M	$52.4M	3.1%	—	$26.88	0.00%	1 qtr	First report 0
IMMUDelisted IMMUNOMEDICS INC	3M	$43.1M	2.5%	—	—	—	1 qtr	First report 0
ARVN ARVINAS INC COM	3.1M	$40.3M	2.3%	—	$13.16	0.00%	1 qtr	First report 0
RARXDelisted RA PHARMACEUTICALS INC	4.9M	$34M	2.0%	—	—	—	1 qtr	First report 0
TGTX TG Therapeutics Inc	8.2M	$33.6M	2.0%	—	$3.98	0.00%	1 qtr	First report 0
KALVDelisted KALVISTA PHARMACEUTICALS INC	1.4M	$28.5M	1.7%	—	$19.56	0.00%	1 qtr	First report 0
MNTADelisted MOMENTA PHARMACEUTICALS INC	2.6M	$28.2M	1.6%	—	—	—	1 qtr	First report 0
DRNADelisted DICERNA PHARMACEUTICALS INC	2.5M	$26.3M	1.5%	—	—	—	1 qtr	First report 0
EIGRDelisted EIGER BIOPHARMACEUTICALS INC	2.4M	$24.5M	1.4%	—	—	—	1 qtr	First report 0

$1.7B

AUM

Positions

Q4 2018

Filing

HI score · 2.5/5

Quarterly 13F Value Change

Not enough history yet

Activity profile

Q4'18

First report: nothing earlier to compare

Composition

Equity vs derivatives

Equity100%Puts0%Calls0%

Holding period

<1Q100%1-4Q0%1-2Y0%2Y+0%

Q4 2018 Summary

First quarter we have for this fund: 25 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $1.7B across 25 positions.

Portfolio Allocation

Top holdings by portfolio weight

WVE18.38%

ASND15.46%

THOR9.84%

ZGNX5.06%

BCRX5.01%

ORTX4.44%

IFRX4.41%

SLDBN4.20%

MYOV3.55%

EIDX3.45%